WO2012028524A3 - Method for producing a tetranectin-apolipoprotein a-i lipid particle, the lipid particle itself and its use - Google Patents

Method for producing a tetranectin-apolipoprotein a-i lipid particle, the lipid particle itself and its use Download PDF

Info

Publication number
WO2012028524A3
WO2012028524A3 PCT/EP2011/064600 EP2011064600W WO2012028524A3 WO 2012028524 A3 WO2012028524 A3 WO 2012028524A3 EP 2011064600 W EP2011064600 W EP 2011064600W WO 2012028524 A3 WO2012028524 A3 WO 2012028524A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid particle
producing
apolipoprotein
tetranectin
itself
Prior art date
Application number
PCT/EP2011/064600
Other languages
French (fr)
Other versions
WO2012028524A2 (en
Inventor
Martin Bader
Monika Baehner
Adelbert Grossmann
Silke Mohl
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to RU2013111678/15A priority Critical patent/RU2013111678A/en
Priority to EP11749404.7A priority patent/EP2611419A2/en
Priority to MX2013001541A priority patent/MX2013001541A/en
Priority to BR112013004397A priority patent/BR112013004397A2/en
Priority to KR1020137005032A priority patent/KR20130047749A/en
Priority to CN2011800386711A priority patent/CN103068368A/en
Priority to CA2807433A priority patent/CA2807433A1/en
Priority to JP2013526413A priority patent/JP2013544488A/en
Publication of WO2012028524A2 publication Critical patent/WO2012028524A2/en
Publication of WO2012028524A3 publication Critical patent/WO2012028524A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Herein is reported a method for producing a lipid particle comprising the following steps i) providing a first solution comprising denatured apolipoprotein, ii) adding the first solution to a second solution comprising at least two lipids and a detergent but no apolipoprotein, and iii) removing the detergent from the solution obtained in step ii) and thereby producing a lipid particle.
PCT/EP2011/064600 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use WO2012028524A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2013111678/15A RU2013111678A (en) 2010-08-30 2011-08-25 METHOD FOR PRODUCING TETRANEKTIN-APOLIPOPROTEIN A-I PARTICLES OBTAINED THROUGH THE LIPID PARTICLE AND ITS APPLICATION
EP11749404.7A EP2611419A2 (en) 2010-08-30 2011-08-25 Method for producing a tetranectin-apolipoprotein a-1 lipid particle, the lipid particle itself and its use
MX2013001541A MX2013001541A (en) 2010-08-30 2011-08-25 Method for producing a tetranectin-apolipoprotein a-i lipid particle, the lipid particle itself and its use.
BR112013004397A BR112013004397A2 (en) 2010-08-30 2011-08-25 method for producing a lipid particle, the lipid particle itself and its use
KR1020137005032A KR20130047749A (en) 2010-08-30 2011-08-25 Method for producing a tetranectin-apolipoprotein a-i lipid particle, the lipid particle itself and its use
CN2011800386711A CN103068368A (en) 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use
CA2807433A CA2807433A1 (en) 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use
JP2013526413A JP2013544488A (en) 2010-08-30 2011-08-25 Method for producing tetranectin-apolipoprotein AI lipid particles, lipid particles themselves, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008995 2010-08-30
EP10008995.2 2010-08-30

Publications (2)

Publication Number Publication Date
WO2012028524A2 WO2012028524A2 (en) 2012-03-08
WO2012028524A3 true WO2012028524A3 (en) 2012-11-15

Family

ID=44532851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/064600 WO2012028524A2 (en) 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use

Country Status (9)

Country Link
EP (1) EP2611419A2 (en)
JP (1) JP2013544488A (en)
KR (1) KR20130047749A (en)
CN (1) CN103068368A (en)
BR (1) BR112013004397A2 (en)
CA (1) CA2807433A1 (en)
MX (1) MX2013001541A (en)
RU (1) RU2013111678A (en)
WO (1) WO2012028524A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044718A1 (en) 2012-02-29 2015-02-12 Hoffmann-La Roche Inc. On-column enzymatic cleavage
CN103408669B (en) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 GLP-1 analog fusion, and its production and use
AU2018397957B2 (en) 2017-12-28 2024-05-23 Takeda Pharmaceutical Company Limited Cationic lipids
DE202019003092U1 (en) * 2019-07-24 2020-01-17 Ruth-Maria Korth Test for the determination of proteophospholipids and FIDA formulas for the determination of protective factors to be balanced with substrates
CN112546201A (en) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 Application of artificial lipoprotein particle apoA-IV fat body in treatment and/or prevention of diabetes
CN116396358B (en) * 2023-06-08 2023-08-29 时夕(广州)生物科技有限公司 Preparation and application of bone-targeted nano lipid particles

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) * 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
US5928644A (en) * 1990-09-17 1999-07-27 Biotech Australia Pty Limited T-cell epitopes
WO2005065708A2 (en) * 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
FR2915490A1 (en) * 2007-04-26 2008-10-31 Univ Joseph Fourier Etablissem FORMATION OF PROTEOLIPOSOMES CONTAINING MEMBRANE PROTEINS USING A CELLULAR PROTEIN SYNTHESIS SYSTEM
WO2009097587A2 (en) * 2008-01-30 2009-08-06 The Rockefeller University Nanoscale bound bilayers, methods of use and production

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500941C2 (en) 1989-08-16 1994-10-03 Algy Persson Method and apparatus for cutting a preparation
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
EP0972838B1 (en) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
EP1276754A4 (en) 2000-04-14 2005-04-06 Nuvelo Inc Materials and methods relating to lipid metabolism
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
CA2443365C (en) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
PE20050438A1 (en) 2003-10-20 2005-06-14 Esperion Therapeutics Inc PHARMACEUTICAL FORMULAS, METHODS AND DOSING REGIMES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
US20060019870A1 (en) 2004-01-28 2006-01-26 O'donnell Francis E Jr Apoprotein cochleate compositions
WO2006125304A1 (en) 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
CN101489577B (en) 2006-06-01 2013-10-16 蒙特利尔心脏病学研究所 Method and compound for the treatment of valvular disease
CN101889022A (en) * 2007-10-08 2010-11-17 阿纳福公司 Trimeric IL-1Ra
JP5539962B2 (en) 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ Nanostructure suitable for sequestering cholesterol

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) * 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
US5928644A (en) * 1990-09-17 1999-07-27 Biotech Australia Pty Limited T-cell epitopes
WO2005065708A2 (en) * 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
FR2915490A1 (en) * 2007-04-26 2008-10-31 Univ Joseph Fourier Etablissem FORMATION OF PROTEOLIPOSOMES CONTAINING MEMBRANE PROTEINS USING A CELLULAR PROTEIN SYNTHESIS SYSTEM
WO2009097587A2 (en) * 2008-01-30 2009-08-06 The Rockefeller University Nanoscale bound bilayers, methods of use and production

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEVY D ET AL: "Reconstitution of the sarcoplasmic reticulum Ca<2+>-ATPase: mechanisms of membrane protein insertion into liposomes during reconstitution procedures involving the use of detergents", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1107, no. 2, 30 June 1992 (1992-06-30), pages 283 - 298, XP027464334, ISSN: 0005-2736, [retrieved on 19920630], DOI: 10.1016/0005-2736(92)90415-I *
SANTOS H D L ET AL: "Na,K-ATPase reconstituted in liposomes: effects of lipid composition on hydrolytic activity and enzyme orientation", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM, NL, vol. 41, no. 4, 10 April 2005 (2005-04-10), pages 239 - 248, XP027803517, ISSN: 0927-7765, [retrieved on 20050410] *
SEDDON A M ET AL: "Membrane proteins, lipids and detergents: not just a soap opera", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1666, no. 1-2, 3 November 2004 (2004-11-03), pages 105 - 117, XP004617558, ISSN: 0005-2736, DOI: 10.1016/J.BBAMEM.2004.04.011 *
See also references of EP2611419A2 *

Also Published As

Publication number Publication date
WO2012028524A2 (en) 2012-03-08
KR20130047749A (en) 2013-05-08
JP2013544488A (en) 2013-12-19
RU2013111678A (en) 2014-10-10
CA2807433A1 (en) 2012-03-08
EP2611419A2 (en) 2013-07-10
CN103068368A (en) 2013-04-24
BR112013004397A2 (en) 2017-06-27
MX2013001541A (en) 2013-03-18

Similar Documents

Publication Publication Date Title
WO2012028524A3 (en) Method for producing a tetranectin-apolipoprotein a-i lipid particle, the lipid particle itself and its use
WO2012123014A3 (en) A current limitation system for limiting the effects of a fault in a dc grid and a method of operating a current limitation system
WO2013158182A3 (en) Method of making a sandwich panel
WO2012014076A3 (en) Liver organoid, uses thereof and culture method for obtaining them
ZA201109191B (en) Mehtod for manufacturing composite connecting rods,and connecting rods produced according to the method
EP2543507A4 (en) Laminate, method for producing same, and functional element using same
WO2015028324A3 (en) A method for producing modified resveratrol
WO2012163532A3 (en) Biodegradable composite material
WO2011000879A3 (en) A method for producing a fermented milk product
WO2011031849A3 (en) Anionic lipids and lipid nanostructures and methods of producing and using same
EP2624314A4 (en) Solar-cell module and manufacturing method therefor
KR101882026B1 (en) Methods for reducing the width of the unbonded region in soi structures and wafers and soi structures produced by such methods
EP2647655A4 (en) High molecular compound, method for producing same, and light-emitting element
WO2013003297A3 (en) Stator core module, stator core assembly and process for assembling a stator core assembly
EP2679826A4 (en) Impeller, rotor comprising same, and impeller manufacturing method
WO2012114122A3 (en) Construction panel
EP2433778A3 (en) Method for reducing differential shrinkage in stereolithography
WO2013034616A3 (en) Capacitor component
EP2580441A4 (en) System and method for throttle-loss recovery and electrical power generation in a spark-ignition engine
WO2013084160A3 (en) Graphene composite and a method of manufacturing a graphene composite
WO2011034551A3 (en) Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2013030342A3 (en) Non-planar photovoltaic device
WO2012034053A3 (en) Increasing the concentration of terpene compounds in liquids
WO2012076271A3 (en) Photovoltaic (pv)-psa composite and use for producing pv modules by liquid embedding
WO2011126604A3 (en) System and method for processing data

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180038671.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11749404

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011749404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011749404

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2807433

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/001541

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013526413

Country of ref document: JP

Kind code of ref document: A

Ref document number: 20137005032

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013111678

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013004397

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013004397

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130225